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SUMMARY
Organogenesis and tissue development occur through sequential stepwise processes leading to increased lineage restriction and loss of
pluripotency. An exception to this appears in the adult human breast, where rare variant epithelial cells exhibit pluripotency andmulti-
lineage differentiation potential when removed from the signals of their nativemicroenvironment. This phenomenon provides a unique
opportunity to study mechanisms that lead to cellular reprogramming and lineage plasticity in real time. Here, we show that primary
humanmammary epithelial cells (HMECs) lose expression of differentiatedmammary epithelialmarkers in amanner dependent onpara-
crine factors and epigenetic regulation. Furthermore, we demonstrate that HMEC reprogramming is dependent on gene silencing by the
DNAmethyltransferase DNMT3A and loss of histone transcriptional marks following downregulation of the methyltransferase DOT1L.
These results demonstrate that lineage commitment in adult tissues is context dependent and highlight the plasticity of somatic cells
when removed from their native tissue microenvironment.
INTRODUCTION
Tissue development is orchestrated by stepwise progres-
sion of primitive multipotent progenitor cells giving rise
to and differentiating into increasingly lineage-committed
progenitors (Reya et al., 2001). During embryonic mam-
mary gland development, the prospective mammary bud
develops as a specialization of the uncommitted surface
ectoderm (Macias and Hinck, 2012; Watson and Khaled,
2008). Microenvironmental signals, including crosstalk
between the surface ectoderm and mesenchymal cells,
are essential for mammary fate specification during this
period; in the absence of specific growth factors and
signals, mammary buds fail to organize or properly
develop (Macias andHinck, 2012). By birth, lineage restric-
tion is established in the mammary epithelium and this
highly specialized glandular structure, composed of bilay-
ered epithelium of luminal and basal/myoepithelial (ME)
cells, is organized into an extensive system of ducts and
alveoli (Macias and Hinck, 2012; Van Keymeulen et al.,
2011).
Despite restriction during development, mammary
epithelial cells exhibit substantial plasticity in settings
such as ex vivo culture, transplantation, wound healing,
and tumorigenesis (Locke and Clark, 2012). The bulk pop-
ulation of primary human mammary epithelial cells
(HMECs) isolated from breast tissue rapidly undergoes
Rb-mediated senescence after 5–10 population doublings
(Brenner et al., 1998; Foster and Galloway, 1996); however,
rare proliferative clones, called variant HMECs (vHMECs),
invariably emerge from primary cultures.
Apart from their proliferative potential, vHMECs display
radically altered differentiation potential compared with
HMECs (Garbe et al., 2009; Keller et al., 2012). In contrast
to early-passage HMECs, vHMECs do not express many of
the characteristic differentiation markers of mammary
epithelial cells. Moreover, vHMECs display metaplastic dif-
ferentiation potential, able to generate glandular structures
or stratified squamous epithelium dependent on the 3D
culture conditions. The latter structures exhibit full
epidermal differentiation with expression of epidermal
markers K10 and involucrin (Keller et al., 2012). Further-
more, when transformed, vHMECs generate aggressive,
poorly differentiated metaplastic cancers with squamous,
glandular, and papillary histologies, in contrast to early-
passage HMECs which predominantly generate breast ade-
nocarcinomas (Keller et al., 2012).
The origin of vHMECs is not known. vHMECs are present
at a frequency of 1/100,000–1/250,000 and do not express
the CDKN2a/p16 cell-cycle inhibitor due to promoter
methylation (Foster and Galloway, 1996; Huschtscha
et al., 1998; Hinshelwood et al., 2009). Therefore, it has
been suggested that vHMECs represent a residual primitive
population persisting in the adult breast (Bean et al., 2007;
Holst et al., 2003; Roy et al., 2013), analogous to CDKN2a-
negative cells identified in the esophagus (Wang et al.,
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2011). However, the appearance of vHMECs in culture as
rare colonies arising after a long latency period is reminis-
cent of the nature and frequency of somatic cell reprogram-
ming by defined factors typical in most induced pluripo-
tent stem cell (iPSC) protocols (Takahashi and Yamanaka,
2006). Therefore, it is possible that vHMECs are epigeneti-
cally reprogrammed from lineage-committed precursors in
a process resembling iPSCs. Supporting this, emergence of
vHMECs is dependent on media composition. In serum-
free media, vHMEC colonies arise 2–4 weeks after the
bulk population of HMECs has undergone CDKN2a/p16-
dependent growth arrest (Holst et al., 2003; Keller et al.,
2012; Romanov et al., 2001). However, in media formula-
tions that contain serum, vHMECs do not emerge (Stamp-
fer et al., 1980), suggesting that microenvironmental
factors may be important in controlling escape from
growth arrest and/or dedifferentiation.
Interestingly, epigenetic modification of HMEC chro-
matin has been shown both locally and globally during
progression to vHMECs. As vHMECs develop, DNA
methylation occurs rapidly at CDKN2a and other targeted
areas, similar to those methylated in breast cancer (Locke
et al., 2015). As methylation of CDKN2a increases, global
loss of H3K27methylation occurs, suggesting that a coordi-
nated epigenetic program could be responsible for HMEC
dedifferentiation (Hinshelwood et al., 2009).
Here, we determined that the transition of HMEC to
vHMEC is a model of epigenetic reprogramming, and iden-
tified specific mechanisms by which lineage-committed
HMECs reprogram to a more primitive state. We conclude
that reprogramming of lineage-committedHMECs requires
gene silencing via coordinated regulation of both DNA and
histone methylation.
RESULTS
HMECs Lose Their Identity in the Absence of Native
Microenvironmental Signals
To characterize the phenotype of HMECs during culture,
we derived HMECs from enzymatically dissociated reduc-
tion mammoplasty samples and analyzed these cells at
different time points. In addition, to understand how
media composition affects cellular differentiation and plas-
ticity, we grew cells in either serum-free mammary epithe-
lial growth medium (MEGM), which leads to vHMEC for-
mation after 40–50 days, or in serum-containing medium
(SCM), which leads to permanent cellular senescence
(Stampfer and Bartley, 1985).
As previously described, when cultured in MEGM,
HMECs exhibited an initial proliferative arrest character-
ized by upregulation of CDKN2a expression and senescent
morphology (Figure 1A). After 35–50 days, rare clones of
small, refractive, proliferating cells overcame growth arrest
and exhibited CDKN2a silencing; these cells possess
extended proliferative capacity but are not immortalized.
qPCR analysis revealed that, compared with early-passage
HMECs, vHMECs had decreased expression of a panel of
genes associated with mammary epithelial differentiation.
These genes include basal/ME-specific OXTR and THY1, as
well as luminal-specific PGR and KRT19 (Figure 1B). These
data confirm that vHMECs exhibit an undifferentiated
phenotype.
In contrast to MEGM, cells grown in SCM initially prolif-
erated quickly, but exhibited growth arrest after 5–10 pop-
ulation doublings and never generated vHMECs (Fig-
ure 1A), behavior consistent with previous descriptions of
HMECs grown in SCM (Stampfer and Bartley, 1985). Inter-
estingly, unlike cells grown in MEGM, cells in SCM did not
exhibit repression of mammary lineage differentiation
genes even after several passages (Figure 1C). Therefore,
the emergence and growth of vHMECs is dependent on
media composition, which also affects loss of HMEC line-
age identity in culture.
We next compared global gene expression profiles of
early-passage HMECs, growth-arrested HMECs, or vHMECs
using gene ontology (GO) analysis on the sets of differen-
tially expressed genes between each group (Figure 1D; data-
set GEO: GSE16058) (Garbe et al., 2009). Interestingly, GO
terms related to epithelial/epidermal differentiation and
development were highly enriched among genes differen-
tially expressed between vHMECs and early-passage
HMECs, consistent with an altered differentiation poten-
tial. Intriguingly, similar GO terms were enriched in a com-
parison of growth-arrested HMECs with the early-passage
cultures, suggesting that loss of lineage commitment
occurred in the bulk population of HMECs even before
vHMECs arise (Figure S1A). In contrast, genes differentially
expressed between vHMECs and growth-arrested HMECs
were limited mainly to DNA replication- or proliferation-
associated genes rather than differentiation-associated
genes (Figure S1B). These data suggest that loss of lineage
identity begins in HMECs prior to the emergence of
vHMECs.
Since it has been reported that artificial silencing of
CDKN2a in HMECs is sufficient to bypass growth arrest
(Novak et al., 2009), we wondered whether loss of CDKN2a
would also be sufficient to induce dedifferentiation of
HMECs into a vHMEC-like state. Accordingly, we stably
reduced CDKN2a in freshly dissociated HMECs using a len-
tiviral short hairpin RNA (shRNA) vector (shCDKN2a) (Fig-
ure S1C). As expected, HMECs infected with shCDKN2a
continued to proliferate exponentially and did not experi-
ence the growth arrest seen in control cells (Figures 1E and
1F). To determine whether shCDKN2a cells lost mammary
lineage identity, we measured the levels of mammary
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epithelial differentiation markers in early- and late-passage
shCDKN2a cells compared with control cells. qPCR anal-
ysis revealed that transcripts for KRT19, PGR, OXTR, and
THY1 were highly expressed in early-passage shCDKN2a
cells at levels similar to those of early-passage control
(shCtrl) cells, and decreased to similar levels as shCtrl cells
in late passage (Figure 1G). Therefore, removing the
CDKN2a senescence barrier does not enable HMECs to
dedifferentiate more rapidly, but enables the bulk popula-
tion of cells to bypass senescence.
Taken together, these data suggest that dedifferentiation
and escape from growth arrest are distinct events during
HMEC culture. The former occurs in the bulk population
of HMECs in a manner dependent on media composition,
while the latter occurs only in a small minority of cells
(vHMECs).
Figure 1. HMECs Lose Lineage Commitment in the Absence of Stromal Cues
(A) Growth curve showing cumulative population doublings over time in primary HMECs grown in MEGM or SCM, n = 3.
(B and C) qPCR analysis of mammary lineage gene expression in HMECs grown in (B) MEGM or (C) SCM at different time points. mRNA levels
are shown relative to the 9-day early culture, n = 3.
(D) Gene ontology (GO) analysis of the set of genes differentially expressed between vHMECs and early-passage HMECs.
(E) Growth curve showing cumulative population doublings over time in HMECs with knockdown of CDKN2a (shCDKN2a) or a firefly
luciferase control (shCtrl), n = 3.
(F) Representative image of an shCDKN2a culture when shCtrl cells are undergoing growth arrest (day 28). shCtrl cells adopt a senescent
morphology while shCDKN2a cells remain small, refractile, and highly proliferative. Scale bars, 100 mm.
(G) qPCR analysis of mammary lineage gene expression in shCtrl or shCDKN2a cultures at different time points, relative to shCtrl (p10), n = 4.
In all panels, error bars indicate the mean ± SEM and replicates are individual patient samples. *p < 0.05, Student’s t test.
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vHMECs Arise from Cells that Undergo Spontaneous
Epigenetic Reprogramming
The origin of vHMECs is not clear. Although it has been
suggested that vHMECs are the outgrowth of a pre-existing
rare population of CDKN2a-methylated cells that reside in
the breast epithelium (Holst et al., 2003; Roy et al., 2013),
our findings suggest that they may alternatively arise
from dedifferentiation of lineage-committed cells that
spontaneously silence the CDKN2a promoter. This would
agree with the finding that HMECs can rapidly methylate
and suppress CDKN2a during culture (Hinshelwood et al.,
2009). Therefore, we next asked whether vHMECs arise
spontaneously from epigenetic reprogramming of cells
without CDKN2a silencing or whether they pre-exist in
HMEC cultures prior to the growth arrest period.
To assess this, we developed an assay to label HMECs that
may potentially give rise to vHMECs. Our approach was to
permanently mark early-passage cells with a promoter that
invariably demonstrates CpG-island DNA methylation in
vHMECs as a tool to trace epigenetic alterations during
vHMEC progression. In addition to CDKN2a, vHMECs
exhibit widespread differences in DNA methylation versus
early-passage HMECs (Novak et al., 2009). We analyzed
genes previously shown to be silenced in vHMECs and
found that the nestin (NES) promoter was consistently
methylated in vHMECs, but not in early-passage HMECs.
NES is a neural stem cell gene that is also expressed inmam-
mary epithelial stem/progenitor cells and is used in this
study as a marker to track de novo DNA methylation (Cre-
gan et al., 2007; Li et al., 2007).
To assess the ability of HMECs to undergo de novo
methylation, we engineered a lentiviral vector coupling
the NES promoter upstream of a GFP transgene, so that
GFP expression is dependent on the methylation status
of the exogenous NES promoter (NES:GFP, Figure 2A).
Freshly dissociated HMECs from reduction mammoplasty
tissues were transduced with NES:GFP, selected in puromy-
cin, then purified to >99% homogeneity by fluorescence-
activated cell sorting (FACS) (Figures 2B and S2A). Upon
plating, early-passage NES:GFP cells remained GFP+ before
and during senescence (Figure 2C).
Long-term culture of FACS-purified NES:GFP+ HMECs
consistently led to the generation of vHMECs with reduced
GFP expression, compared with nearby growth-arrested
cells (Figure 2D). Furthermore, we performed methyl-
ation-specific PCR of the exogenous NES:GFP promoter us-
ing primers that spanned the promoter-transgene junc-
tion. This demonstrated that the exogenous NES:GFP
promoter was methylated in vHMECs that arose from
GFP+ cells, but was not methylated in early-passage GFP+
cultures (Figure 2E). As expected, the endogenous CDKN2a
and NES promoters were also methylated in the vHMECs,
but not in early-passage cells (Figures 2E and 2F). Impor-
tantly, promoter methylation was reversed and expression
of bothNES andGFPwere rescued in the bulk population of
cells upon treatment with the DNA methyltransferase in-
hibitor decitabine (DAC) (Figures 2E–2H). These findings
suggest that vHMECs that exhibit NES silencing by DNA
methylation can be derived from cells that do not exhibit
NESmethylation.
To determine how promoter methylation might affect
lineage dedifferentiation of HMECs, we compared expres-
sion levels of mammary lineage differentiation genes in
early-passage HMECs, vHMECs, and vHMECs treated
withDAC. As a control,CDKN2amRNA levels were rescued
withDAC treatment, showing relief of DNAmethylation at
gene promoters (Figure S2B). Treatment of vHMECs with
DAC led to re-expression of KRT19 and OXTR, but not
PGR or THY1 (Figure 2I). Importantly, both KRT19 and
OXTR have CpG islands in their gene promoters, while
PGR and THY1 do not. This confirms that de novo DNA
methylation is involved in HMEC reprogramming but
that it likely coordinates with other epigenetic modifica-
tions to fully control dedifferentiation.
To further assess whether vHMECs originate either from
rare pre-existing cells or from stochastic epigenetic reprog-
ramming of lineage-committed cells, we used fluctuation
analysis, an approach originally developed by Luria and
Delbruck to study the emergence of phage-resistant clones
in bacterial cultures (Luria, 1951). In fluctuation analysis, a
mass culture of cells is split into many smaller bottlenecks
and expanded, after which a selection pressure is applied to
screen for the number of cells that survive. If the resistant
clones arise stochastically during culture, their distribution
amongst the bottlenecks will follow a Poisson distribution;
however, if they are pre-existing the distribution will be
non-Poisson, with some cultures containing no clones
and some containing large amounts.
We applied fluctuation analysis to the HMEC system by
dividing the mass HMEC culture into small bottlenecks of
5,000 cells each, and counting the number of vHMECs
generated by each bottleneck. As a control, HMECs were
also cultured en masse until the final passage before variant
formation and plated at densities equal to those of the
bottleneck cultures (Figure S2C).
Fluctuation analysis revealed that the bottlenecks did not
follow a Poisson distribution (Figures S2D–S2F, chi-square
p = 0.0034). A large number of bottlenecked cultures con-
tained no vHMECs while others contained a large number
of vHMECs (Figure S2F). These data are consistent with the
existence of a rare pre-existing vHMEC population within
breast tissue, as previously reported (Holst et al., 2003).
However, it is inconsistent with previous data and our
data that show de novomethylation ofCDKN2a andNES oc-
curs during vHMEC outgrowth (Figure 2; Hinshelwood
et al., 2009).
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Figure 2. vHMECs Arise from HMECs Following Epigenetic Reprogramming
(A) Schematic of the construct used to GFP-label primary HMECs with an exogenous NES promoter; methylation-specific PCR primers are
shown in red.
(B) Quantification of flow cytometry analysis of the percentage of GFP+ versus GFP cells in HMEC cultures before and after FACS puri-
fication of GFP+ cells, n = 3.
(C) Representative images of untransduced, unsorted, and GFP+-sorted NES:GFP cultures at the point of growth arrest. The minority GFP
cells present in the unsorted cultures are absent from the FACS-purified cultures. Scale bars, 100 mm.
(D) Representative low-power (top) and high-power (bottom) images of a vHMEC colony derived from FACS-purified GFP+ cells showing
GFP+ senescent cells (arrows) adjacent to GFP vHMECs. Scale bars, 100 mm.
(E and F) Methylation-specific PCR of the (E) exogenous NES:GFP promoter, CDKN2a, or (F) endogenous NES promoter region, in early-passage
HMECs, vHMECs, or in vHMECs treated with decitabine (DAC) from (E) NES:GFP or (F) untransduced cultures. U, unmethylated; M, methylated.
(G) qPCR analysis of NES expression in HMECs, vHMECs, and vHMECs treated with DAC, n = 3.
(H) Flow-cytometry analysis of high GFP expression in early-passage NES:GFP HMECs, decreased expression in NES:GFP vHMECs, and partial
rescue by treatment of NES:GFP vHMECs with DAC.
(I) qPCR analysis of mammary lineage gene expression in early HMECs, vHMECs, and vHMECs treated with DAC, relative to vHMEC, n = 4.
In all panels, error bars indicated the mean ± SEM and replicates are individual patient samples. *p < 0.05, Student’s t test.
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vHMEC Reprogramming Is Partially Controlled by
DNMT3a
To reconcile this discrepancy, we reasoned that a rare sub-
population of HMECs residing in breast tissue is capable
of giving rise to metaplastic vHMECs, but that this popula-
tion undergoes epigenetic reprogramming through DNA
methylation or othermodifications. To test this, wemanip-
ulated the level of the de novo DNA methyltransferase,
DNMT3a, in HMECs. Strikingly, when DNMT3a was
silenced in early-passage HMECs, cells did not bypass
senescence or form vHMEC colonies (Figures 3A, 3B, and
S3A). Conversely, overexpression of DNMT3a markedly
increased the number of vHMEC colonies without
decreasing the time to colony formation or affecting
cellular proliferation (Figures 3C–3E and S3B). Surprisingly,
DNMT3a overexpression did not increase promoter
methylation or expression of CDKN2a andNES, but greatly
affected both promoter methylation and expression of the
mammary lineage gene KRT19 (representative patient sam-
ples in Figures 3F, 3G, and S3C).OXTRwas alsomethylated
by DNMT3a; however, its expression was unchanged, indi-
cating it may be regulated by additional epigenetic modifi-
cations (Figures 3F and 3G). Together, these data indicate
that de novomethylation of specific gene promoter regions
is a defining epigenetic event in the generation vHMECs
from a rare population of HMECs and that loss of mam-
mary lineage differentiation occurs through epigenetic
modifications.
DOT1L Inhibition Enhances the Efficiency of vHMEC
Cell Reprogramming
Induction and maintenance of pluripotency is dependent
on multiple epigenetic processes including histone
methylation, DNA methylation, and chromatin remodel-
ing (Papp and Plath, 2013). To identify additional epige-
netic processes that might play a role in imparting a
primitive phenotype on lineage-committed HMECs, we
profiled the expression of 184 chromatin-modifying fac-
tors in matched pre- and post-stasis HMECs using qPCR
arrays. From this collection of chromatin modifiers, we
identified four factors that exhibited differential expres-
sion in vHMECs compared with early-passage precursors
after validation (DOT1L, KDM6B, SMYD3, and PRMT8)
(Figure S4A).
Figure 3. vHMEC Reprogramming Is
Partially Controlled by DNMT3a
(A) Growth curve showing cumulative pop-
ulation doublings over time in cultures with
stable depletion of DNMT3a (shDNMT3a) by
two different lentiviral short hairpins versus
shCtrl.
(B) Quantitative analysis of the number of
vHMEC colonies formed by cultures lacking
DNMT3a (shDNMT3a) versus the firefly
luciferase control (shCtrl), n = 3.
(C) Quantitative analysis of the number of
vHMEC colonies formed by DNMT3a-over-
expressing cultures versus the LacZ control,
n = 4.
(D) Latency of vHMEC colony formation,
defined as the number of days required for
vHMECs to appear, in LacZ versus DNMT3a
overexpressing cultures, n = 4.
(E) Growth curve showing cumulative pop-
ulation doublings over time in cultures with
LacZ or DNMT3a overexpression, n = 3.
(F) Methylation-specific PCR of gene pro-
moters in early-passage HMECs (EP) versus
vHMECs (vH) expressing LacZ or DNMT3a.
(G) Representative image of qPCR analysis of
expression of DNA methylation-regulated
genes in early HMECs versus vHMECs ex-
pressing LacZ or DNMT3a.
In all panels, error bars indicate the mean ±
SEM and replicates are individual patient
samples. *p < 0.05, Student’s t test.
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Of these factors we focused on DOT1L, a histone lysine
methyltransferase solely responsible for mono-, di-, and
tri-methylation of Lys79 of histone H3 (Nguyen and
Zhang, 2011). This chromatin mark is enriched in actively
transcribed promoters and gene bodies and plays an impor-
tant role in transcriptional elongation (Feng et al., 2002;
Yao et al., 2011). Notably, DOT1L and H3K79 methylation
were recently identified as an epigenetic barrier to iPSC
reprogramming by maintaining expression of lineage-spe-
cific genes, and inhibition of DOT1L enhances the effi-
ciency of iPSC reprogramming by blocking its anti-silencer
effect on these genes (Onder et al., 2012). Given the simi-
larities between iPSC reprogramming and vHMEC forma-
tion, we wondered whether DOT1L played a similar role
in the generation of vHMECs. Since DOT1L is downregu-
lated in vHMECs versus early-passage HMECs in a
medium-dependent manner (Figures 4A and S4B), we
wondered whether depletion of DOT1L would enhance
the efficiency of vHMEC reprogramming. Interestingly, sta-
ble knockdown of DOT1L in freshly dissociated HMECs
significantly increased the frequency of vHMEC colony for-
mation (Figures 4B and 4C). Moreover, DOT1L knockdown
significantly shortened the latency period between growth
arrest and appearance of vHMEC colonies (Figures 4D and
4F). A similar effect was observed when cells were treated
with FED1, a specific chemical inhibitor of DOT1L (Yao
et al., 2011) (Figures 4E and 4F). Importantly, DOT1L deple-
tion did not affect CDKN2a expression or growth rate in
early-passage cultures, suggesting that shDOT1L cells do
not just bypass stasis entirely.
Histone Methylation by DOT1L Is Necessary to
Maintain HMEC Differentiation
As in iPSC-reprogrammed fibroblasts, H3K79 may play
an important role in preventing silencing of differentiation
genes, and therefore in vHMEC reprogramming. As DOT1L
is the sole known enzyme responsible for H3K79 methyl-
ation, a mark of actively transcribed chromatin (Feng
et al., 2002), we wondered whether alterations in this
mark contribute to the silencing ofmammary-specific tran-
scripts. We examined the total levels of H3K79me2 in
vHMECs, as well as the levels of H3K79me2 at the pro-
moters of genes silenced during vHMEC progression. Inter-
estingly, we observed a decrease in global H3K79me2 levels
Figure 4. DOT1L Loss Enhances the Efficiency of Reprogramming
(A) qPCR of DOT1L mRNA levels in early-passage HMECs versus vHMECs, n = 5.
(B) Western blot of DOT1L and p16/INK4a protein levels following stable knockdown of DOT1L (shDOT1L) in early-passage HMECs.
(C) Number of vHMEC colonies generated by shDOT1L or shCtrl control cultures, shown relative to shCtrl, n = 3.
(D and E) Growth curves showing cumulative population doublings over time in cultures with (D) DOT1L depletion (shDOT1L) or (E)
chemical inhibition with FED1, n = 3.
(F) Latency of vHMEC colony formation, defined as the number of days required after growth arrest for vHMECs to appear, in cells with
DOT1L depletion (shDOT1L) or FED1 treatment, n = 3.
In all panels, error bars indicate the mean ± SEM and replicates are individual patient samples. *p < 0.05, Student’s t test.
Stem Cell Reports j Vol. 9 j 943–955 j September 12, 2017 949
in vHMECs compared with early-passage HMECs, corre-
lating with the level of DOT1L (Figures 5A and 5B). In addi-
tion, chromatin immunoprecipitation (ChIP) assays of
H3K79me2 at the promoters of THY1 and OXTR revealed
decreased enrichment of H3K79me2 around the transcrip-
tional start sites of mammary lineage genes in vHMECs
compared with early-passage cells (Figure 5C). H3K79me2
levels were also moderately decreased in growth-arrested
HMECs at the THY1 locus, though not at OXTR. Therefore,
at both a global and local level, H3K79 methylation is pro-
gressively depleted as cells lose lineage commitment and
become dedifferentiated.
We also examined whether the decrease in H3K79me2
could be induced by loss of DOT1L in early-passage
HMECs. Within 7 days, DOT1L knockdown by shRNA led
to decreased H3K79me2 levels in HMECs, both globally
(Figure 5D) and locally at the THY1 and OXTR promoters
(Figure 5E). Collectively, these data show that DOT1L is
necessary to maintain di-methylation of H3K79 at pro-
moters of lineage-related genes. Consistent with changes
in H3K79me2 levels, there was reduced expression of line-
age-committed genes upon knockdown of DOT1L (Fig-
ure 5F), suggesting that DOT1L depletion negatively regu-
lates mammary epithelial differentiation. Interestingly,
Figure 5. Histone Methylation by DOT1L
Is Necessary for Maintaining HMEC Differ-
entiation
(A and B) Representative western blot (A)
and densitometric quantitation (B) of
H3K79me2 levels in early-passage cultures
versus vHMECs, n = 3.
(C) Chromatin immunoprecipitation (ChIP)
of H3K79me2 levels in early-passage HMECs,
growth-arrested cultures, or vHMECs (shown
as the percent of input normalized to the
total H3 level). SAT2 is a negative control,
n = 3.
(D) Western blot of H3K79me2 levels in
shDOT1L cultures versus shCtrl.
(E) ChIP analysis of H3K79me2 in shDOT1L
versus shCtrl HMECs at early-passage (shown
as the percent of input normalized to the
total H3 level).
(F) qPCR analysis of mammary lineage gene
expression in early-passage shDOT1L versus
shCtrl HMECs analyzed 1 week after DOT1L
depletion by shRNA, n = 3.
(G) Graphical depiction of the mechanism of
HMEC reprogramming showing coordinated
alterations in DNA and histone methylation
to promote vHMEC formation.
In all panels, error bars indicate the mean ±
SEM and replicates are individual patient
samples. n.d., not determined; *p < 0.05,
Student’s t test.
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DOT1L depletion significantly reduced only THY1 and
PGR, not KRT19 or OXTR. This is consistent with our
DNA methylation results that both KRT19 and OXTR are
also regulated by promotermethylation (Figure 2I), empha-
sizing that multiple epigenetic mechanisms collaborate to
control dedifferentiation.
As DOT1L inhibition accelerated the dedifferentiation
and outgrowth of vHMECs, we examined whether exoge-
nous overexpression of DOT1L in early-passage HMECs
might prevent or slow vHMEC reprogramming. However,
despite robust overexpression of DOT1L and dramatically
increased global levels of H3K79me2 (Figure S5A), the fre-
quency of vHMEC outgrowth was unchanged (Figure S5B).
Therefore, DOT1L is necessary but not sufficient to prevent
epigenetic reprogramming, and other factors likely coop-
erate with DOT1L to maintain mammary lineage commit-
ment in HMEC cultures (Figure 5G).
DISCUSSION
The surprising plasticity of adult somatic cells has
become an unanticipated theme of contemporary devel-
opmental biology, but the study of plasticity has re-
mained largely descriptive and the precise mechanisms
of dedifferentiation remain elusive. vHMECs are an inter-
esting example of plasticity, as these cells arise from line-
age-committed mammary epithelial cells that reprogram
to a multipotent surface-ectoderm-like state capable of
generating stratified epidermis (Keller et al., 2012).
Hence, the intent of this study was to leverage the
vHMEC model system to study loss of lineage commit-
ment in real time, something that has been difficult to
achieve with other systems.
Using this approach, we uncovered several important
findings. First, our observations reinforce the importance
of tissue architecture and stromal influences in the regula-
tion of both cell growth and differentiation and under-
score the highly plastic nature of somatic cells even
without genetic mutations. When removed from instruc-
tive signals of the tissue microenvironment, lineage-
committed mammary epithelial cells can spontaneously
reprogram to a primitive state. Although the relevant
microenvironmental factors remain to be determined,
the requirement of specific signals for maintenance of
lineage commitment is illustrated by the finding that
HMECs grown in serum do not lose expression of line-
age-specific genes. Presently it is unclear whether the sig-
nals that maintain lineage commitment of HMECs are
secreted molecules, structural/mechanical cues from the
tissue architecture, hetero-/homotypic interactions with
other mammary epithelial cells in vivo, or some combina-
tion of the above. However, the fact that vHMECs did not
form in SCM, nor did the cells dedifferentiate in this
growthmedium, suggests that hormonal and/or paracrine
signaling mechanisms may be essential for maintaining
lineage commitment.
Second, our data suggest that vHMECs originate from
epigenetic reprogramming of non-vHMECs. vHMEC
outgrowth involves de novo DNA methylation and gene
silencing of both cell-cycle regulators (i.e., CDKN2a) and
lineage-specific genes (NES, THY1, OXTR, PGR, and
KRT19). Previously, it was unknown whether vHMECs
arose from a rare subpopulation of breast epithelial cells
that had already silenced these genes or from lineage-
committed precursors by epigenetic reprograming. Here,
we show by stable introduction of the NES promoter into
pre-stasis cells that a de novomethylation event occurs dur-
ing the transition from lineage-committed HMECs to
vHMECs. Because vHMECs form only rarely in the absence
of the de novo DNA methyltransferase, DNMT3a, it is very
likely that vHMEC outgrowth is dependent on de novo
DNAmethylation of CDKN2a and other genes. As reported
by others, and demonstrated here by silencing of CDKN2a
by shRNA, CDKN2a silencing is the only event that is
required for HMECs to escape proliferative arrest (Foster
and Galloway, 1996). However, it has been shown that a
large number of other genes are methylated and/or differ-
entially expressed in vHMECs, suggesting that DNA
methylation is not limited to the CDKN2a locus and that
DNA methylation-independent mechanisms of gene
silencing are also at play (Novak et al., 2009). Therefore,
it is likely that epigenetic reprogramming of lineage-
committed cells involves a coordinated process of DNA
methylation and histone modification (Hinshelwood
et al., 2009). Indeed, the four mammary lineage differenti-
ation genes investigated in this study were downregulated
through different mechanisms that involved a combina-
tion of both these processes. However, the temporal nature
of reprogramming is not entirely clear from our experi-
ments. While the transcriptional silencing of lineage-spe-
cific genes appears to be gradual over the period of tissue
culture and likely is mediated by the loss of DOT1L, it is un-
clear whether all of the DNAmethylation events occur as a
single coordinated step or if HMECs gradually accumulate
epigenetic modifications, such as CDKN2a methylation
early, followed by other DNA methylation and histone al-
terations until escape from senescence as dedifferentiated
variant colonies.
Third, we implicate a new mechanism by which epige-
netic reprogramming is controlled in breast tissue: H3K79
methylation by DOT1L.We found that DOT1L is necessary
to maintain lineage commitment in HMECs, significantly
accelerating vHMEC outgrowth when it is depleted. This
acceleration of vHMEC reprogramming by DOT1L loss is
correlated with reduced levels of H3K79me2 and can be
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mimicked by blocking the enzymatic activity of DOT1L by
FED1. Therefore, it is likely that the erasure of active
H3K79me2 marks over time is an important precursor to
the silencing of lineage genes that accompanies vHMEC
outgrowth. How H3K79me2 reduction leads to escape
from growth arrest remains an unanswered question; how-
ever, it is likely through regulation of CDKN2a. One possi-
bility is that the H3K79me2markmay protect against DNA
methylation of CDKN2a and other actively transcribed
genes, a property that has been attributed to other active
histone marks such as trimethyl-H3K4 (Li and Liu, 2004).
While there is no evidence as yet of a specific link between
H3K79me2 and DNA methylation, future studies in the
vHMEC system should address whether H3K79me2 can
prevent the recruitment of DNMT3a to genes that are
methylated in vHMECs.
Lastly, how reprogramming relates to in vivo breast
biology is currently unknown. Recent work by Tlsty’s
group demonstrated the existence of rare cells in human
breast tissue that show CDKN2a methylation, lack THY1
expression, and demonstrate a pluripotent phenotype
(Holst et al., 2003; Roy et al., 2013). However, while in vivo
CDKN2a-negative cells of the breast share many features
with vHMECs, they cannot be equated solely on the basis
of similar immunophenotypes. Furthermore, even if they
are equivalent, these cells may have different origins.
Whether a vHMEC reprogramming-like event can occur
in vivo therefore remains an open question. In addition,
while an attractive hypothesis, it is not clear whether
dedifferentiation or reprogramming of HMECs may play
a role in the generation of metaplastic breast cancer.
While CDKN2a DNA methylation is common in breast
cancer, it is not specifically linked with poorly differenti-
ated or metaplastic tumors (Herman et al., 1995; Hui
et al., 2000).We previously reported that oncogenic trans-
formation of primary CD10+ basal HMECs generates
metaplastic tumors, similar to those generated by trans-
formation of vHMECs, and these cells are also the source
of adherent HMEC cultures that spontaneously generate
vHMECs in culture (Keller et al., 2012). Therefore, it is
possible that metaplastic breast cancers in xenografts
and in human patients might result from dedifferentia-
tion of CD10+ basal cells during oncogenic transforma-
tion, as previously suggested (Keller et al., 2012). Consis-
tent with this notion, DOT1L levels are decreased in the
metaplastic xenografts compared with other tumors
(data not shown).
While there is more research needed to link vHMECs
arising in cell culture with the in vivo equivalent in the
mammary gland or breast cancer, this work sheds impor-
tant light on the epigenetic basis of cellular plasticity,
which could prove useful in understanding cellular reprog-
ramming in other systems.
EXPERIMENTAL PROCEDURES
Isolation of Primary HMECs
Reduction mammoplasty tissues were obtained from the Depart-
ment of Pathology at Tufts Medical Center in full compliance
with Institutional Research Board (IRB) guidelines. As the samples
were de-identified prior to receipt, the requirement for written con-
sent was waived by the IRB. Tissue processing to single cells was
carried out as previously described (Keller et al., 2012). In short, tis-
sue was minced into 1-mm pieces, resuspended in digestion me-
dium (DMEM/F12 [Corning], 20 ng/mL human epidermal growth
factor [hEGF], 10 mg/mL human insulin, 500 ng/mL hydrocorti-
sone, 1.5 mg/mL collagenase, and 125 units/mL hyaluronidase
[Sigma]) and incubated overnight at 37C to release organoids.
Stromal cells were depleted by plating on a tissue culture dish for
2 hr at 37C. Following incubation, non-adherent organoids
were harvested, washed with PBS and red blood cell lysis buffer
(Sigma), further digested in 0.05% trypsin/EDTA, and filtered
through 40-mm mesh prior to plating.
Cell Culture
To initiate primary HMEC cultures, 106 dissociated cells were
plated on 10-cm tissue culture plates. Unless otherwise stated, all
cultures were grown in MEGM (Lonza) with weekly subculture.
SCM consisted of DMEM/F12 with 20 ng/mL recombinant hEGF,
10 mg/mL recombinant human insulin, and 500 ng/mL hydrocor-
tisone (Sigma) with penicillin/streptomycin (Gibco). For methyl-
ation experiments, cells were treated with 500 nM decitabine
(DAC) or DMSO for 72 hr, refreshing the drug daily.
For growth curves, cells were subcultured weekly with 0.05%
trypsin-EDTA and 500,000 of the recovered cells were replated.
At each passage, the total number of recovered cells was counted
and the population doublings were computed as log2(number of
recovered cells/number of plated cells). After growth arrest, the cul-
ture was maintained without passaging until vHMEC colonies
were seen by microscopic inspection. Following vHMEC appear-
ance, cultures were maintained with weekly subculture as
described above. Quantitation of vHMEC colony formation was
performed by daily microscopic inspection.
Fluctuation Analysis
For fluctuation analysis, freshly dissociated HMECs were plated
either as amass culture of 100,000 cells or as 20 bottleneck cultures
of 5,000 cells each. Cells were passaged until proliferation slowed,
at which point (1) 250,000 cells from each bottleneck were plated
on a 10-cm dish and (2) the mass culture was also divided into 20
replicates of 250,000 cells each, to assess vHMEC colony forma-
tion. After 30 days, the number of vHMECs in each dish was visu-
ally determined by crystal violet staining and microscopy.
Retrovirus/Lentivirus Production and Generation of
Stable Cell Lines
Packaging of replication-defective lentivirus and retrovirus was
performed as previously described (Keller et al., 2012). To generate
lentivirus, 293T cells were cotransfected with the vesicular stoma-
titis virus envelope (pCMV-VSV-G), the gag-pol genes (pCMV-
D8.2Dvpr), and the appropriate lentiviral expression or shRNA
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construct in a 1:2:3 ratio, respectively. For generation of retrovirus,
293T cells were cotransfected with the pC10-A packaging plasmid
with the appropriate retroviral expression or shRNA vector at a 1:1
ratio. Transfections were performed using Fugene 6 transfection re-
agent according to the manufacturer’s protocol (Promega). Viral
supernatants were harvested from the transfected cells 48 and
72 hr post transfection and filtered through a 0.45-mm syringe
filter.
To generate stable lines of primaryHMECs expressing exogenous
transgenes or shRNAs, viral supernatant was applied to the cells
96 hr after initial dissociation and plating. Cells were infected
with viral supernatants for 4 hr with 5 mg/mL protamine sulfate
(Sigma), fed with normal growth medium, and a second infection
was performed 24 hr later. Two days after transfection, cells were
selected with 2 mg/mL puromycin (Sigma) or 10 mg/mL blasticidin
(Life Technologies) and maintained in selective media until com-
plete death of a mock-infected control plate, then MEGM for
long-term growth.
Lentiviral/Retroviral Vectors
Retroviral DOT1L and DNMT3a shRNA clones, as well as DOT1L
cDNA clones, were provided by Tamer S. Onder. The lentiviral
CDKN2a and luciferase shRNAs for CDKN2a knockdown experi-
ments were obtained from Addgene (#22264 and #20958).
To generate the NES:GFP construct, the proximal 1,000 base
pairs upstream of the NES transcriptional start site was amplified
by PCR from a bacterial artificial chromosome template and
cloned into the CSCG vector upstream of the GFP coding
sequence. The resulting NES:GFP cassette was then PCR amplified
from the CSCG template with flanking attB sites added during
PCR. The attB-tailed NES:GFP cassette was first cloned into
pDONR221, then transferred to the promoterless pLenti X1-
puro backbone (Addgene, #17297) using the Gateway BP Clonase
II enzyme kit (Life Technologies) according to the manufacturer’s
instructions.
qRT-PCR
For all qPCR experiments, total RNAwas extracted from cells using
the RNeasy Mini Kit (Qiagen). cDNA was generated from 1 mg of
RNA with the iScript cDNA synthesis kit (Bio-Rad) according to
the manufacturer’s instructions. qPCR was performed with 50 ng
of cDNA using SYBR Green Supermix (Bio-Rad) with a primer con-
centration of 250 nMeach (forward and reverse). Three-step ampli-
fication and quantitation was performed on a CFX96 Real-time
Thermal Cycler (Bio-Rad) using the following program: initial
denaturation at 95C for 3 min, followed by 40 cycles of 95C
denaturation for 30 s, annealing at 60C 30 s, and extension at
72C for 30 s. Threshold cycle (Ct) valueswere converted to relative
gene expression values using the 2DDCtmethod. Primer sequences
are provided in Supplemental Experimental Procedures.
qPCR Arrays
For analysis of chromatin-modifying factors, we used the
Epigenetic Chromatin Modification Enzymes PCR Array (Qiagen/
SABiosciences, PAHS-085Z). For these arrays, we used the associ-
ated RT2 First Strand cDNA kit (Qiagen #330401) and the RT2
qPCR Mastermix (Qiagen #330522) for cDNA synthesis and
qPCR, respectively, according to the manufacturer’s instructions.
Gene expression valueswere normalized to themeanof five house-
keeping genes present on each array. Hits were validated by qPCR.
Methylation-Specific PCR
For methylation analysis of gene promoters, genomic DNAwas ex-
tracted from the cells using the PureLink Genomic DNA Mini Kit
(Life Technologies). Cytosine deamination was performed using
the MethylCode bisulfite conversion kit (Life Technologies) ac-
cording to themanufacturer’s instructions. The bisulfite-converted
genomic DNAwas then used as the template for a genomic PCR re-
action using primers specific either for the methylated (uncon-
verted) or unmethylated (C / U converted) CpG islands near
the transcriptional start sites of NES, NES:GFP, Krt19, OXTR, and
CDKN2a. The PCR products were analyzed by gel electrophoresis
in 2% agarose. Primer sequences are provided in Supplemental
Experimental Procedures.
Western Blotting
To evaluate total levels of H3K79me2 and H3, we performed west-
ern blot analysis on acid-extracted nuclear lysates. Cellmembranes
were lysed by suspension in PBS/0.05% Triton X-100, 2 mM PMSF,
and 0.02% sodium azide at a density of 107/mL for 10 min on ice.
Nuclei were pelleted by centrifugation at 2,000 rpm for 10 min at
4C, washed in PBS/PMSF/NaN3, resuspended in 0.2 N HCl, acid-
extracted overnight at 4C with rotation, and centrifuged at
2,000 rpm for 10 min, and the acid-insoluble pellet was discarded.
For all other western blotting, protein lysates were prepared by re-
suspension of harvested cell pellets in RIPA buffer (50 mM Tris,
150 mM NaCl, 2 mM EDTA, 1% NP-40, and 0.1% SDS [pH 7.4])
on ice for 20 min with occasional agitation, followed by passage
five times through a 20-gauge needle.
Protein samples were subjected to SDS-PAGE and transferred
to either 0.45 mm or 0.2 mm nitrocellulose (Bio-Rad) for 1 hr at
100 V using the Criterion system (Bio-Rad) in 25 mM Tris,
200 mM glycine buffer with 20% methanol. Following transfer,
membranes were blocked in 2% milk in Tris-buffered saline (TBS;
50 mM Tris, 150 mM NaCl) with 0.1% Tween 20 (TBST) for 1 hr
at room temperature, followed by overnight incubation in the
blocking buffer and primary antibody at 4C. Membranes were
washed with TBST, incubated with horseradish peroxidase-conju-
gated secondary antibodies for 1 hr at room temperature, washed
in TBST, and developed with either West Pico or West Dura ECL
substrates (Pierce) according to the manufacturer’s protocol. Anti-
body information is provided in Supplemental Experimental
Procedures.
Flow Cytometry
For analysis of GFP positivity of NES:GFP cultures, cells were trypsi-
nized, washed twice with FACS buffer (2% FBS/PBS), resuspended
at 106 cells/mL, and either sorted for GFP+ cells or analyzed on a
flow cytometry to determine levels of GFP expression.
Chromatin Immunoprecipitation
ChIP was performed using the MagnaChIP A kit (Millipore) ac-
cording to the manufacturer’s recommended protocol. In brief,
two 15-cm of near-confluent HMECs were crosslinked with 1%
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formaldehyde for 10 min at room temperature, followed by
quenching with glycine for 5 min at room temperature. The
crosslinked chromatin was sheared by sonication in a Misonix
3000 tip sonicator (power level 3.0, five cycles of 20 s ‘‘on,’’ 60 s
‘‘off’’). 10% of the sheared crosslinked chromatin was used in
each immunoprecipitation.
Antibody incubation and elution steps were performed using
protein A magnetic beads according to manufacturer’s instruc-
tions. Immunoprecipitated chromatin was quantified by genomic
qPCR, with the following parameters: initial denaturation for
3 min at 95C, then 40 cycles of denaturation at 95C for 10 s, an-
nealing at 60C for 30 s, and extension at 72C for 30 s. Cycle
thresholds were converted to linear quantities using the 2DCt for-
mula and expressed as a percentage of the original input. The anti-
bodies and primers used for ChIP are provided in Supplemental
Experimental Procedures.
Gene Ontology Analysis
For transcriptomic GO analysis of HMECs during culture, the data-
set GEO: GSE16058was downloaded from theGEOwebsite (Garbe
et al., 2009).
A list of differentially expressed genes between early-passage
HMECs, growth-arrested HMECs, and vHMECs was generated us-
ing the GEO2Rweb tool, and the top 200 genes with a false discov-
ery rate (FDR) < 0.05 were used for GO analysis. Enrichment of GO
terms was performed by hypergeometric overlap using the Broad
Institute’s online tool against the GO Biological Process gene
sets. The enriched gene sets were selected from the top 20 most
highly enriched GO terms.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and five figures and can be found with this article on-
line at http://dx.doi.org/10.1016/j.stemcr.2017.06.019.
AUTHOR CONTRIBUTIONS
Conceptualization, C.K.; Methodology, J.L.B., A.S., M.S., A.W.-C.,
W.Z., P.J.K., J.M., J.B., T.O., and C.K.; Investigation, J.L.B., A.S.,
M.S., A.W.-C., W.Z., P.J.K., J.M., J.B., T.O., and C.K.; Acquisition
of data, J.L.B., A.S., M.S., A.W.-C., W.Z., P.J.K., J.M., J.B., T.O., and
C.K.; Analysis and interpretation of data, J.L.B., A.S., M.S.,
A.W.-C., W.Z., P.J.K., J.M., J.B., T.O., and C.K.; Writing, J.L.B.,
A.S., and C.K; Funding Acquisition, C.K.
ACKNOWLEDGMENTS
We acknowledge Lisa Arendt and Ravi Subramanian for technical
and scientific assistance and advice. We thank Dr. Stephen Naber
for assistance with the procurement of human reductionmammo-
plasty tissue samples and Kayla Gross for careful reading and edit-
ing of the manuscript.
This work was supported by funding from the Raymond &
Beverly Sackler Convergence Laboratory and grants from
ArtBeCAUSE, the Breast Cancer Research Foundation, and the
NIH (NICDH HD073035 and NCI CA170851). J.L.B. is supported
by award K12GM074869 from the NIGMS.
Received: June 22, 2016
Revised: June 28, 2017
Accepted: June 29, 2017
Published: August 3, 2017
REFERENCES
Bean, G.R., Ibarra Drendall, C., Goldenberg, V.K., Baker, J.C., Jr.,
Troch, M.M., Paisie, C., Wilke, L.G., Yee, L., Marcom, P.K., Kimler,
B.F., et al. (2007). Hypermethylation of the breast cancer-associ-
ated gene 1 promoter does not predict cytologic atypia or correlate
with surrogate end points of breast cancer risk. Cancer Epidemiol.
Biomarkers Prev. 16, 50–56.
Brenner, A.J., Stampfer, M.R., and Aldaz, C.M. (1998). Increased
CDKN2a expression with first senescence arrest in human mam-
mary epithelial cells and extended growth capacity with CDKN2a
inactivation. Oncogene 17, 199–205.
Cregan, M.D., Fan, Y., Appelbee, A., Brown, M.L., Klopcic, B., Kop-
pen, J., Mitoulas, L.R., Piper, K.M., Choolani, M.A., Chong, Y.S.,
et al. (2007). Identification of nestin-positive putative mammary
stem cells in human breastmilk. Cell Tissue Res. 329, 129–136.
Feng, Q., Wang, H., Ng, H.H., Erdjument-Bromage, H., Tempst, P.,
Struhl, K., and Zhang, Y. (2002). Methylation of H3-lysine 79 is
mediated by a new family of HMTases without a SET domain.
Curr. Biol. 12, 1052–1058.
Foster, S.A., and Galloway, D.A. (1996). Human papillomavirus
type 16 E7 alleviates a proliferation block in early passage human
mammary epithelial cells. Oncogene 12, 1773–1779.
Garbe, J.C., Bhattacharya, S., Merchant, B., Bassett, E., Swisshelm,
K., Feiler, H.S., Wyrobek, A.J., and Stampfer, M.R. (2009). Molecu-
lar distinctions between stasis and telomere attrition senescence
barriers shown by long-term culture of normal human mammary
epithelial cells. Cancer Res. 69, 7557–7568.
Herman, J.G., Merlo, A., Mao, L., Lapidus, R.G., Issa, J.P., Davidson,
N.E., Sidransky, D., and Baylin, S.B. (1995). Inactivation of the
CDKN2/CDKN2a/MTS1 gene is frequently associated with aber-
rant DNA methylation in all common human cancers. Cancer
Res. 55, 4525–4530.
Hinshelwood, R.A., Melki, J.R., Huschtscha, L.I., Paul, C., Song,
J.Z., Stirzaker, C., Reddel, R.R., and Clark, S.J. (2009). Aberrant de
novo methylation of the CDKN2aINK4A CpG island is initiated
post gene silencing in association with chromatin remodeling
and mimics nucleosome positioning. Hum. Mol. Genet. 18,
3098–3109.
Holst, C.R., Nuovo, G.J., Esteller, M., Chew, K., Baylin, S.B., Her-
man, J.G., and Tlsty, T.D. (2003). Methylation of CDKN2a(INK4a)
promoters occurs in vivo in histologically normal human mam-
mary epithelia. Cancer Res. 63, 1596–1601.
Hui, R., Macmillan, R.D., Kenny, F.S., Musgrove, E.A., Blamey,
R.W., Nicholson, R.I., Robertson, J.F., and Sutherland, R.L.
(2000). INK4a gene expression and methylation in primary breast
cancer: overexpression of CDKN2aINK4a messenger RNA is a
marker of poor prognosis. Clin. Cancer Res. 6, 2777–2787.
Huschtscha, L.I., Noble, J.R., Neumann, A.A., Moy, E.L., Barry, P.,
Melki, J.R., Clark, S.J., and Reddel, R.R. (1998). Loss of
CDKN2aINK4 expression by methylation is associated with
954 Stem Cell Reports j Vol. 9 j 943–955 j September 12, 2017
lifespan extension of human mammary epithelial cells. Cancer
Res. 58, 3508–3512.
Keller, P.J., Arendt, L.M., Skibinski, A., Logvinenko, T., Klebba, I.,
Dong, S., Smith, A.E., Prat, A., Perou, C.M., Gilmore, H., et al.
(2012). Defining the cellular precursors to human breast cancer.
Proc. Natl. Acad. Sci. USA 109, 2772–2777.
Li, H., Cherukuri, P., Li, N., Cowling, V., Spinella, M., Cole, M.,
Godwin, A.K., Wells, W., and DiRenzo, J. (2007). Nestin is ex-
pressed in the basal/myoepithelial layer of the mammary gland
and is a selective marker of basal epithelial breast tumors. Cancer
Res. 67, 501–510.
Li, J.X., and Liu, H.L. (2004). The relationship of DNAmethylation
and histone methylation. Yi Chuan 26, 267–270.
Locke, W.J., and Clark, S.J. (2012). Epigenome remodelling in
breast cancer: insights from an early in vitro model of carcinogen-
esis. Breast Cancer Res. 14, 215.
Locke, W.J., Zotenko, E., Stirzaker, C., Robinson, M.D., Hinshel-
wood, R.A., Stone, A., Reddel, R.R., Huschtscha, L.I., and Clark,
S.J. (2015). Coordinated epigenetic remodeling of transcriptional
networks occurs during early breast carcinogenesis. Clin. Epige-
netics 7, 52.
Luria, S.E. (1951). The frequency distribution of spontaneous
bacteriophage mutants as evidence for the exponential rate of
phage reproduction. Cold Spring Harb. Symp. Quant. Biol. 16,
463–470.
Macias, H., and Hinck, L. (2012). Mammary gland development.
Wiley Interdiscip. Rev. Dev. Biol. 1, 533–557.
Nguyen, A.T., and Zhang, Y. (2011). The diverse functions of Dot1
and H3K79 methylation. Genes Dev. 25, 1345–1358.
Novak, P., Jensen, T.J., Garbe, J.C., Stampfer, M.R., and Futscher,
B.W. (2009). Stepwise DNA methylation changes are linked to
escape fromdefined proliferation barriers andmammary epithelial
cell immortalization. Cancer Res. 69, 5251–5258.
Onder, T.T., Kara, N., Cherry, A., Sinha, A.U., Zhu, N., Bernt, K.M.,
Cahan, P., Marcarci, B.O., Unternaehrer, J., Gupta, P.B., et al.
(2012). Chromatin-modifying enzymes as modulators of reprog-
ramming. Nature 483, 598–602.
Papp, B., and Plath, K. (2013). Epigenetics of reprogramming to
induced pluripotency. Cell 152, 1324–1343.
Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001).
Stem cells, cancer, and cancer stem cells. Nature 414, 105–111.
Romanov, S.R., Kozakiewicz, B.K., Holst, C.R., Stampfer, M.R.,
Haupt, L.M., and Tlsty, T.D. (2001). Normal human mammary
epithelial cells spontaneously escape senescence and acquire
genomic changes. Nature 409, 633–637.
Roy, S., Gascard, P., Dumont, N., Zhao, J., Pan, D., Petrie, S., Mar-
geta, M., and Tlsty, T.D. (2013). Rare somatic cells from human
breast tissue exhibit extensive lineage plasticity. Proc. Natl. Acad.
Sci. USA 110, 4598–4603.
Stampfer, M., Hallowes, R.C., and Hackett, A.J. (1980). Growth of
normal human mammary cells in culture. In Vitro 16, 415–425.
Stampfer, M.R., and Bartley, J.C. (1985). Induction of transforma-
tion and continuous cell lines from normal human mammary
epithelial cells after exposure to benzo[a]pyrene. Proc. Natl.
Acad. Sci. USA 82, 2394–2398.
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent
stem cells from mouse embryonic and adult fibroblast cultures
by defined factors. Cell 126, 663–676.
Van Keymeulen, A., Rocha, A.S., Ousset,M., Beck, B., Bouvencourt,
G., Rock, J., Sharma, N., Dekoninck, S., and Blanpain, C. (2011).
Distinct stem cells contribute to mammary gland development
and maintenance. Nature 479, 189–193.
Wang, W.C., Wu, T.T., Chandan, V.S., Lohse, C.M., and Zhang, L.
(2011). Ki-67 and ProExC are useful immunohistochemical
markers in esophageal squamous intraepithelial neoplasia. Hum.
Pathol. 42, 1430–1437.
Watson, C.J., and Khaled, W.T. (2008). Mammary development in
the embryo and adult: a journey of morphogenesis and commit-
ment. Development 135, 995–1003.
Yao, Y., Chen, P., Diao, J., Cheng, G., Deng, L., Anglin, J.L., Prasad,
B.V., and Song, Y. (2011). Selective inhibitors of histone methyl-
transferase DOT1L: design, synthesis, and crystallographic studies.
J. Am. Chem. Soc. 133, 16746–16749.
Stem Cell Reports j Vol. 9 j 943–955 j September 12, 2017 955
